Microbiological profile in chronic granulomatous disease patients in a single Brazilian primary immunodeficiencies center

Main Article Content

Aimé Filippini Bifulco Oliveira
Antonio Carlos Pastorino
Mayra de Barros Dorna
Ana Paula Beltran Moschione Castro
José Roberto Mendes Pegler
Beni Morgenstern
Magda Maria Sales Carneiro-Sampaio

Keywords

- Chronic Granulomatous Disease, Staphylococcal Infections, Aspergillus, Mycobacterium, Abscess, Pediatrics

Abstract

Background: Chronic granulomatous disease (CGD) is a rare primary immunodeficiency. Infections of the lungs, skin, lymph nodes, and liver are the hallmark of CGD with frequent initial manifestations of the disease. The aim of the present study was to describe the sites of infections and their causative agents in 38 CGD pediatric patients.
Methods: This was a retrospective single-center cohort study comprising CGD patients, and followed for over last 40 years at the Allergy and Immunology Unit of a tertiary hospital in São Paulo, Brazil. Sites of infections and their causative agents were described.
Results: A total of 38 patients were included (36 males and 2 females). Median age at the onset of symptoms was 45 days (7 days–7 years) and that at the time of diagnosis was 23 months (1 month–12 years); 31.6% of the parents reported death of relatives during childhood and 21% (8 cases) had another male family member with CDG. The most common infections were pneumonia (81.6%), skin infections (50.0%), adenitis (42.1%), and liver abscess (23.7%). In all, 188 cultures were positive (85.6% for bacteria and 14.4% for fungi). The most prevalent bacterial agents were Staphylococcus sp. (12.4%), Staphylococcus aureus (11.2%), and Klebsiella pneumoniae (9.3%). Aspergillus sp. and Candida sp. were 56% and 22.2% of the isolated fungi, respectively. Mycobacterium tuberculosis was isolated in 5.6% and Mycobacterium bovis in 0.9% (only in 1 patient) of cultures.


Conclusion: Staphylococcus sp., Staphylococcus aureus, and Aspergillus sp. were the most frequent agents in this cohort. M. tuberculosis should be considered in endemic areas. Detection of infectious agents drives to find adequate treatment and benefits the evolution of patients with CGD.

Abstract 72 | PDF Downloads 61 XML Downloads 3 HTML Downloads 0

References

1. Holland SM. Chronic granulomatous disease. Hematol Oncol Clin North Am. 2013;27(1): 89–99. https://doi.org/10.1016/j.hoc.2012.11.002
2. Chiriaco M, Salfa I, Di Matteo G, Rossi P, Finocchi A. Chronic granulomatous disease: Clinical, molecular, and therapeutic aspects. Pediatr Allergy Immunol. 2016;27(3):242–53. https://doi.org/10.1111/pai.12527
3. Arnold DE, Heimall JR. A review of chronic granulomatous disease. Adv Ther. 2017;34(12):2543–57. https://doi.org/10.1007/s12325-017-0636-2
4. Magnani A, Brosselin P, Beauté J, de Vergnes N, Mouy R, Debré M, et al. Inflammatory manifestations in a single-center cohort of patients with chronic granulomatous disease. J Allergy Clin Immunol. 2014;134(3):655–62.e8. https://doi.org/10.1016/j.jaci.2014.04.014
5. Gennery A. Recent advances in understanding and treating chronic granulomatous disease. F1000 Res. 2017;6:1427. https://doi.org/10.12688/f1000research.11789.1
6. Gallin JI, Alling DW, Malech HL, Wesley R, Koziol D, Marciano B, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med. 2003;348(24):2416–22. https://doi.org/10.1056/NEJMoa021931
7. Connelly JA, Marsh R, Parikh S, Talano JA. Allogeneic hematopoietic cell transplantation for chronic granulomatous disease: Controversies and state of the art. J Pediatric Infect Dis Soc. 2018;7(Suppl 1):S31–9. https://doi.org/10.1093/jpids/piy015
8. Ministério da Saúde. Portal da Saúde. Sistema de Informações sobre Nascidos Vivos ( SINASC). Live births in Brazil 2019 [Internet]. Available from: http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sinasc/cnv/nvuf.def Accessed December 21, 2020.
9. Latin American Society for Immunodeficiencies (LASID). Statistic Register of PID cases [Internet]. Available from http://www.bragid.org.br/_download/registro/estatisticas_2018_08.pdf. Accessed December 21, 2020.
10. Kutukculer N, Aykut A, Karaca NE, Durmaz A, Aksu G, Genel F, et al. Chronic granulomatous disease: Two decades of experience from a pediatric immunology unit in a country with high rate of consanguineous marriages. Scand J Immunol. 2019;89(2):e12737. https://doi.org/10.1111/sji.12737
11. Fattahi F, Badalzadeh M, Sedighipour L, Movahedi M, Fazlollahi MR, Mansouri SD, et al. Inheritance pattern and clinical aspects of 93 Iranian patients with chronic granulomatous disease. J Clin Immunol. 2011;31(5):792–801. https://doi.org/10.1007/s10875-011-9567-x
12. Al-Zadjali S, Al-Tamemi S, Elnour I, AlKindi S, Lapoumeroulie C, Al-Maamari S, et al. Clinical and molecular findings of chronic granulomatous disease in Oman: Family studies. Clin Genet. 2015;87(2):185–9. https://doi.org/10.1111/cge.12351
13. Gao LW, Yin QQ, Tong YJ, Gui JG, Liu XY, Feng XL, et al. Clinical and genetic characteristics of Chinese pediatric patients with chronic granulomatous disease. Pediatr Allergy Immunol. 2019;30(3):378–86. https://doi.org/10.1111/pai.13033
14. Bortoletto P, Lyman K, Camacho A, Fricchione M, Khanolkar A, Katz BZ. Chronic granulomatous disease, a large, single-center US experience. Pediatr Infect Dis J. 2015;34(10):1110–4. https://doi.org/10.1097/INF.0000000000000840
15. Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore). 2000;79(3):155–69. https://doi.org/10.1097/00005792-200005000-00003
16. van den Berg JM, van Koppen E, Ahlin A, Belohradsky BH, Bernatowska E, Corbeel L, et al. Chronic granulomatous disease: The European experience. PLoS ONE. 2009;4(4):e5234. https://doi.org/10.1371/journal.pone.0005234
17. Wu J, Wang WF, Zhang YD, Chen TX. Clinical features and genetic analysis of 48 patients with chronic granulomatous disease in a single center study from Shanghai, China (2005–2015): New studies and a literature review. J Immunol Res. 2017;2017:8745254. https://doi.org/10.1155/2017/8745254
18. de Oliveira-Junior EB, Zurro NB, Prando C, Cabral-Marques O, Pereira PV, Schimke LF, et al. Clinical and genotypic spectrum of chronic granulomatous disease in 71 Latin American patients: First report from the LASID registry. Pediatr Blood Cancer. 2015;62(12):2101–7. https://doi.org/10.1002/pbc.25674
19. Martire B, Rondelli R, Soresina A, Pignata C, Broccoletti T, Finocchi A, et al. Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: An Italian multicenter study. Clin Immunol. 2008;126(2):155–64. https://doi.org/10.1016/j.clim.2007.09.008
20. Conti F, Lugo-Reyes SO, Blancas Galicia L, He J, Aksu G, Borges de Oliveira E Jr, et al. Mycobacterial disease in patients with chronic granulomatous disease: A retrospective analysis of 71 cases. J Allergy Clin Immunol. 2016;138(1):241–8. e3. https://doi.org/10.1016/j.jaci.2015.11.041
21. Rawat A, Vignesh P, Sharma A, Shandilya JK, Sharma M, Suri D, et al. Infection profile in chronic granulomatous disease: A 23-year experience from a tertiary care center in north India. J Clin Immunol. 2017;37(3):319–28. https://doi.org/10.1007/s10875-017-0382-x
22. Marciano BE, Spalding C, Fitzgerald A, Mann D, Brown T, Osgood S, et al. Common severe infections in chronic granulomatous disease. Clin Infect Dis. 2015;60(8):1176–83. https://doi.org/10.1093/cid/ciu1154
23. Buvelot H, Posfay-Barbe KM, Linder P, Schrenzel J, Krause KH. Staphylococcus aureus, phagocyte NADPH oxidase and chronic granulomatous disease. FEMS Microbiol Rev. 2017;41(2):139–57. https://doi.org/10.1093/femsre/fuw042
24. Argemi X, Hansmann Y, Prola K, Prévost G. Coagulase-negative staphylococci pathogenomics. Int J Mol Sci. 2019;20(5):1215. https://doi.org/10.3390/ijms20051215
25. King J, Henriet SSV, Warris A. Aspergillosis in chronic granulomatous disease. J Fungi (Basel). 2016;2(2):pii: E15. https://doi.org/10.3390/jof2020015
26. Bennett N, Maglione PJ, Wright BL, Zerbe C. Infectious complications in patients with chronic granulomatous disease. J Pediatric Infect Dis Soc. 2018;7(Suppl 1):S12–S17. https://doi.org/10.1093/jpids/piy013
27. Blumental S, Mouy R, Mahlaoui N, Bougnoux ME, Debré M, Beauté J, et al. Invasive mold infections in chronic granulomatous disease: A 25-year retrospective survey. Clin Infect Dis. 2011;53(12):e159–69. https://doi.org/10.1093/cid/cir731
28. Ministério Da Saúde. Manual de recomendações para o controle da tuberculose no Brasil, 2ª edição atualizada. 2019. Available from: http:bvsms.saude.gov.brbvs/bvs/publicacoes/manual_recomendações_controle_tuberculose_brasil_2_ed.pdf. Accessed April 28, 2020.
29. Falcone EL, Holland SM. Invasive fungal infection in chronic granulomatous disease: Insights into pathogenesis and management. Curr Opin Infect Dis. 2012;25(6):658–69. https://doi.org/10.1097/QCO.0b013e328358b0a4
30. Lublin M, Bartlett DL, Danforth DN, Kauffman H, Gallin JI, Malech HL, et al. Hepatic abscess in patients with chronic granulomatous disease. Ann Surg. 2002;235(3):383–91. https://doi.org/10.1097/00000658-200203000-00010